Alle Studien
Einschreibung auf EinladungPHASE3INTERVENTIONELL

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

This study, called ADVANCE EXTENSION, is designed for people with a specific type of lung condition called WHO Group 1 Pulmonary Arterial Hypertension (PAH). Participants must have already taken part in an earlier study looking at the drug Ralinepag. The main goal is to understand how well Ralinepag works and if it's safe over a longer period. Participants will continue to receive Ralinepag alongside any other PAH medications they are already taking. It's an "open-label" study, meaning everyone involved, including the participants and doctors, will know they are receiving Ralinepag. This research helps us learn more about the long-term use of this medication for PAH.

Auf einen Blick

Worum geht es in dieser Studie?

This study, known as ADVANCE EXTENSION, is a continuation for people who have already been involved in a study testing a drug called Ralinepag for a serious lung condition called Pulmonary Arterial Hypertension (PAH). PAH is a rare disease where the blood vessels in the lungs become narrow, making it difficult for the heart to pump blood through them. This can lead to symptoms like breathlessness and tiredness.

The main purpose of this study is to gather more information about the long-term effects of Ralinepag. Specifically, doctors want to see how well the drug continues to work over time to help manage PAH, and to track any side effects that might occur with long-term use. The study is "open-label," which means that everyone involved – the participants, the doctors, and the researchers – will know that Ralinepag is being given. This is different from a "blinded" study where some people might receive a placebo (a dummy pill).

If you join this study, you will continue to receive Ralinepag. This will be in addition to any other medicines you are already taking for your PAH. The information collected from this study is really important because it helps medical professionals understand how to best use Ralinepag to help people live better with PAH in the long run. The study will continue until the drug is approved and available more widely, or if the study needs to end for other reasons.

Wichtige Erkenntnisse

  • This study is for people with PAH who have previously taken Ralinepag.
  • Its main aim is to understand the long-term safety and effectiveness of Ralinepag.
  • Participants will know they are receiving Ralinepag (it's 'open-label').
  • Ralinepag will be given alongside your usual PAH medications.
  • Regular check-ups and tests will monitor your health and the drug's effects.
  • You can leave the study at any time without affecting your normal care.

Wer könnte berechtigt sein?

To be considered for this study, you must have already taken part in a previous study involving the drug Ralinepag for your Pulmonary Arterial Hypertension (PAH). You also need to have successfully completed all the required steps of that earlier study.

It's important that you are willing and able to attend all scheduled appointments, follow the treatment plan, and have necessary tests done. If you are a man or woman who could become pregnant, you'll need to agree to use effective contraception throughout the study and for 30 days after taking your last dose of Ralinepag. This also means not trying to become pregnant or making someone pregnant during this time.

Unfortunately, you won't be able to join if you had to stop your previous Ralinepag study because of serious side effects or if you didn't finish all the necessary procedures in that study. You also cannot participate if you decided to stop your involvement in a previous Ralinepag study, are pregnant or breastfeeding, or have recently had a lung or heart/lung transplant since your last Ralinepag study.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I have previously participated in a study involving Ralinepag for PAH.
  2. I completed all the required steps of that previous Ralinepag study.
  3. I am aged 18 years or older.
  4. I am willing to attend all study visits and undergo tests.
  5. If I can become pregnant or make someone pregnant, I agree to use contraception during the study.
  6. I have not had a lung or heart/lung transplant since my last Ralinepag study.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will receive the drug Ralinepag. You will continue to take Ralinepag along with any other medications you are already using for your PAH. If you're coming from a study where you didn't know if you were getting Ralinepag or a placebo, you might have a 16-week period where the dose is adjusted, but you'll still be receiving Ralinepag.

Throughout the study, you'll have regular hospital or clinic visits where you'll be checked by the doctors and nurses. These visits will involve various tests to monitor your health and how you're responding to the medication, such as blood tests or heart and lung assessments. The doctors will also keep track of any side effects you experience.

There's no set total duration for this extension study. You will continue to receive Ralinepag for as long as the study is ongoing, unless you or your doctor decide it's best for you to stop, or if Ralinepag becomes widely available in your area.

Potenzielle Risiken und Vorteile

The potential benefits of taking part include continued access to Ralinepag, which may help manage your PAH, and contributing to important medical research that could help others with PAH in the future. As with any drug, Ralinepag may have side effects, and some could be serious. The research team will carefully monitor you for any problems. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (190)

  • St. Joseph's Hospital and Medical Center-Norton Thoracic Institute
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • University of Arizona
    Verifizierte Postleitzahl
    Tucson, Vereinigte Staaten
  • UCSD Health Sciences
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten
  • Ronald Reagan UCLA Medizinisches Zentrum
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • Keck Hospital of USC
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • VA Greater Los Angeles Healthcare System
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • University of California, Irvine
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten
  • Universitätsklinikum der University of California, Davis
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • Santa Barbara Cottage Hospital
    Verifizierte Postleitzahl
    Santa Barbara, Vereinigte Staaten
  • Stanford Universitätsklinikum
    Verifizierte Postleitzahl
    Stanford, Vereinigte Staaten
  • University of Colorado Hospital
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten
  • National Jewish Health
    Verifizierte Postleitzahl
    Denver, Vereinigte Staaten

Häufige Fragen

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a serious condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood through them. This can cause symptoms like breathlessness and fatigue.

Was ist eine 'Open-Label'-Studie?

In an open-label study, both you and your doctor will know that you are receiving the study drug (Ralinepag). This is different from a 'blinded' study where you might not know if you're getting the drug or a dummy pill.

Will I take Ralinepag instead of my current PAH medicines?

No, you will continue to take Ralinepag in addition to your existing PAH medications. It's meant to work alongside what you're already taking.

What happens if Ralinepag becomes available outside the study?

If Ralinepag gets approved and becomes widely available where you live, the study may end for you, and your doctor can then prescribe it to you if appropriate.

Can I stop participating in the study at any time?

Yes, you are free to withdraw from the study at any point and for any reason, without it affecting your ongoing medical care.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study Evaluating the Long-Term Efficacy and Safety of Rali… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.